Symbicort brought in worldwide sales of $2.7 billion last year, with $1.1 billion of that coming from the US market, where an authorised generic sold under license from AZ has been available since ...

including a generic version of Symbicort and one other undisclosed inhalation product. Symbicort is an asthma and COPD medication with over $3 billion in annual sales, presenting a major market ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper ... with a fast action, in a single inhaler. A Viatris spokesperson said: "Viatris obviously ...

The Federal Trade Commission recently challenged more than 100 patents as improperly listed in the Food and Drug Administration ... on its blockbuster inhaler Symbicort. The company noted ...